# Help Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/help-therapeutics

- Industry: Biotechnology
- Headquarters: Nanjing, China
- Website: www.helptx.com.cn
- Total disclosed funding: $25M
- Latest round: Series C (Nov 29, 2021)
- Investors on record: 5

## About

Based in Nanjing, China, and founded in 2016 by its CEO, Dr. Eugene Wang, Help Therapeutics operates as a biotechnology company that develops induced pluripotent stem cells for the treatment of moderate-to-severe heart failure and tumor immune disease. In November 2021, Help Therapeutics raised USD 25 million in series C funding led by Ming Bioventures, Beisen Medical Fund, and Jolmo Capital. As of 2021, the company's single production line has an annual capacity of 100,000 doses.

The Help Therapeutics platform provides a Chinese bank of induced pluripotent stem cells for storing iPSC lines, stem cell differentiation technologies that enable the large-scale production of highly pure cardiomyocytes, nerve cells, and other cell types from iPSCs, clinical translation, and automatic GMP Grade Manufacturing.

## Funding rounds

- Series C, Nov 29, 2021, $25M — Share Capital, Jolmo Capital, Ming Bioventures, Beisen Medical Fund, Purple Bull Startups

## Investors

- Share Capital (https://capitalatlas.ai/funds/share-capital) — Series C
- Jolmo Capital (https://capitalatlas.ai/funds/jolmo-capital) — Series C
- Ming Bioventures (https://capitalatlas.ai/funds/ming-bioventures) — Series C
- Beisen Medical Fund — Series C
- Purple Bull Startups — Series C